Alan Smiley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alan Smiley has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bernhard Vogler
Department of Chemistry, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
1 shared publication - Christopher R. Apperson
Department of Chemistry, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
1 shared publication - Emily C. Hunt
Department of Chemistry, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
1 shared publication - Luis Mercado
Department of Chemistry, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
1 shared publication - Madushika M. Wimalarathne
Department of Chemistry, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
1 shared publication - Moses Adaji David
Department of Chemistry, The University of Alabama in Huntsville, Huntsville, AL 35899, USA
1 shared publication
Latest Publications
- Open Access
- 19 April 2024
- Published by MDPI AG in Endocrines
- Vol. 5 (2) , 166-185
Male LEW.1WR1 Rats Develop Metabolic Dysfunction, Steatohepatitis, and Liver Damage
Most patients with non-alcoholic steatohepatitis (NASH) have insulin resistance, and there is a near-universal association between NASH and insulin resistance. Insulin resistance induces lipid accumulation in the liver, leading to the development of metabolic syndrome. However, most NASH rodent models fail to develop metabolic syndrome. LEW.1WR1 rats that are 23 weeks old showed increased body mass, epididymal fat, and liver mass, suggesting obesity-driven metabolic dysfunction. We have characterized steatosis, inflammation, Mallory–Denk body formation with hematoxylin and eosin (H&E), and fibrosis with Trichome blue staining. The presence of hepatic fibrosis with other features of NASH described above is one of the major strengths of this model since most of the currently available NASH models do not develop microvesicular steatosis or fibrosis. Together with the other important features of NASH described above, we confirm that male LEW.1WR1 rats develop NASH and insulin resistance with a standard diet.
- 19 April 2024
- Published by MDPI AG in Endocrines
- Vol. 5 (2) , 166-185
Open AccessMale LEW.1WR1 Rats Develop Metabolic Dysfunction, Steatohepatitis, and Liver Damage
Most patients with non-alcoholic steatohepatitis (NASH) have insulin resistance, and there is a near-universal association between NASH and insulin resistance. Insulin resistance induces lipid accumulation in the liver, leading to the development of metabolic syndrome. However, most NASH rodent models fail to develop metabolic syndrome. LEW.1WR1 rats that are 23 weeks old showed increased body mass, epididymal fat, and liver mass, suggesting obesity-driven metabolic dysfunction. We have characterized steatosis, inflammation, Mallory–Denk body formation with hematoxylin and eosin (H&E), and fibrosis with Trichome blue staining. The presence of hepatic fibrosis with other features of NASH described above is one of the major strengths of this model since most of the currently available NASH models do not develop microvesicular steatosis or fibrosis. Together with the other important features of NASH described above, we confirm that male LEW.1WR1 rats develop NASH and insulin resistance with a standard diet.